Mankind Pharma Q4 & FY26 Results: Revenue Up 11.8% YoY to ₹3,443 Cr, Adj. EBITDA Margins at 27.1%
Mankind Pharma reported Q4 FY26 revenue of ₹3,443 crore, up 11.8% YoY, with adjusted EBITDA margins at 27.1%. For FY26, revenue reached ₹14,278 crore, a 17.0% increase. Domestic business grew 14.9%, exports 34.5%. The company maintained its #1 prescription rank.
The announcement contains detailed financial results for the quarter and full year, along with strategic business updates, which are material information for investors and significantly impact the company's valuation and outlook.
The company reported strong year-on-year revenue growth and healthy margins, along with positive business updates and market leadership, indicating a favorable financial performance.
Mankind Pharma Limited has released its investor presentation for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹3,443 crore for Q4 FY26, an increase of 11.8% year-on-year. The adjusted EBITDA margins stood at 27.1% for the quarter.
For the full financial year FY26, the company's revenue from operations grew by 17.0% to ₹14,278 crore compared to ₹12,207 crore in FY25. The domestic business, excluding Consumer Healthcare, grew by 14.9% to ₹11,338 crore, while the Consumer Healthcare segment saw an 8.7% increase to ₹879 crore. Exports business witnessed a significant growth of 34.5% to ₹2,061 crore.
The company highlighted strong performance in its domestic business, driven by double-digit growth in the Mankind domestic business, particularly in cardiac (14.7%) and anti-diabetes (11.6%) therapies. The Consumer Healthcare business grew by 20% year-on-year, led by strong growth in e-commerce.
Key financial metrics for FY26 include a reported EBITDA of ₹3,499 crore and Profit After Tax of ₹1,938 crore. Diluted EPS stood at ₹46.3 for FY26.
Mankind Pharma also detailed its business updates, including expansion in specialty and super-specialty segments, key strengths, and strategy going ahead. The company maintained its #1 rank in prescriptions for the last 9 years. The investor presentation is available on the company's website.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.